Board

Prof. Dr. Erich Schlick,
German national, born in 1952.

Dr. Schlick has over 25 years of experience in the healthcare sector. He spent five
years at the US National Cancer Institute, and over 15 years with BASF Pharma, including
ten years as the executive board member responsible for worldwide R&D. Dr. Schlick
established BASF Pharma's immunology business, and its U.S. biotech centre specializing
in immunology and monoclonal antibodies. From 2001 to September 2005, Dr. Schlick
worked for 3i, where his last position was head of 3i's Healthcare Team in Germany
and as Deputy Head of 3i Healthcare Worldwide. In September 2005, Dr. Schlick joined
Wellington Partners as a General Partner of the Wellington Life Science Fund. Dr.
Schlick is a qualified medical doctor and a professor of immune pharmacology at
the University of Heidelberg. His other board memberships include Immatics (Germany),
Sensimed (Switzerland), Symetis (Switzerland) and Zentralinstitut für Seelische
Gesundheit, Mannheim, University of Heidelberg (University Center for Psychiatry).
Dr. Schlick's past board memberships include the German companies Paion, Trigen,
MBDsys and Elara.

Neil Goldsmith,
British national, domiciled in Switzerland, born in 1963.

Neil Goldsmith co-founded Evolva SA and has been a member of the Board of Directors
of Evolva SA and its Chief Executive Officer since April 2004.
Mr. Goldsmith has a 22 year track record in building successful biotech companies
from the ground up. He was a co-founder of TopoTarget A/S and Personal Chemistry
AB (now called Biotage AB), which are now listed on the Copenhagen and Stockholm
exchanges, respectively. Prior to that, Mr. Goldsmith was CEO of Auda Pharmaceuticals
(acquired by Phytera Inc.), GX Biosystems and PNA Diagnostics (acquired by Boehringer
Mannheim). Previously he was VP Business Development for Pharmacia Biosensor (later
BIAcore AB), and a Board Member of Quadrant Healthcare. Mr. Goldsmith started his
career in biotech at Scientific Generics in Cambridge, UK after a short spell in
consumer marketing. He received a First Class Honours BA Degree in Zoology from
Balliol College, University of Oxford, and is a graduate of the New Enterprise Program
at the Scottish Enterprise Foundation, University of Stirling.

Michel Pettigrew, MBA,
Canadian national, domiciled in Switzerland, born in 1953.

Michel Pettigrew has been a member of the Board of Directors since 2007.
Mr. Pettigrew started his career in 1976 at Procter & Gamble Inc. in Canada, where
he worked in various financial functions. In 1980, he joined the global pharmaceutical
company Bristol-Myers Squibb, where he worked for units in Canada and the United
States, as well as in Europe and Asia. Initially, his responsibilities were in Finance,
but these rapidly grew to include full business accountability as General Manager
of several subsidiaries in different parts of the world. In 2001, Mr. Pettigrew
moved to Ferring Pharmaceuticals, a privately owned research-driven speciality biopharmaceutical
company. He is currently President, Executive Board & Chief Operating Officer of
Ferring Pharmaceuticals, overseeing all sales, marketing and manufacturing activities
around the world. Mr. Pettigrew has a Bachelor of Commerce degree from McGill University
in Montreal, Canada, and a MBA from York University in Toronto, Canada.
He was previously on the Board of Affitech A/S.

Ingelise Saunders,
Danish national, born in 1949.

Ms. Saunders has more than 30 years of experience in the biotech/pharmaceutical
industry. She is currently President and CEO of TD Vaccines A/S. and CEO of Action Pharma A/S.
Previously she was President and CEO of ACE BioSciences (DK) for five years. Prior to that, Ms.
Saunders was CEO for three years of Celltech Pharmaceuticals plc (UK) with global
commercial responsibility, and 16 years with Novo Nordisk in a number of top level
executive management positions both in Denmark and in the UK. Ms. Saunders has a
Cand.Pharm. degree from the University of Copenhagen, Royal Danish School of Pharmacy,
and a Bachelor of Commerce degree in Marketing. Her other board memberships include:
Scandinavian Life Science Invest AB, TopoTarget A/S, ALK-Abello A/S and Nordic Vaccine
A/S (Chairman).

Jean-Philippe Tripet, CFA,
Swiss national, born in 1963.

Mr. Tripet has over 15 years in healthcare venture experience. He is the Chairman
and Managing Partner of Aravis Venture, a Swiss leading venture capital firm, which
he founded in 2001. Previously, Mr. Tripet served as Senior Executive Vice President
of Lombard Odier & Cie, where he headed Equity Asset Management and Research worldwide
and also co-founded and headed the Lombard Odier Immunology Fund. Prior to that,
he was Vice President of Equity Research at Union Bank of Switzerland, Zurich and
London. Mr. Tripet received his Master in business administration from the University
of Geneva. Mr. Tripet's other board memberships include: Omeros (USA), Merlion (Singapore),
S Bio (Singapore), Symetis (Lausanne, Switzerland), Telormedix (Lugano, Switzerland),
Synosia (Basel, Switzerland), and Fondation Fournier-Majoie pour l'Innovation (Belgium).
He was previously a director of Combinature (Germany), Borean (Denmark), ESBATech
(Switzerland) and Athelas (Switzerland).

Sir Tom McKillop,
British national, born in Scotland in 1943

Sir Tom McKillop was educated at Irvine Royal Academy, Glasgow University (where he took a BSc Hons and PhD in Chemistry) and Centre de Mecanique Ondulatoire Appliquee (Paris). He had a long and successful career at ICI, where he held a number of increasingly senior Research and Development positions until his appointment in 1989 as Technical Director and Deputy Chairman of ICI Pharmaceuticals, a role in which he had global responsibility for Research, Development, Medical and Production. In 1994, he was appointed Chief Executive Officer of Zeneca Pharmaceuticals - Zeneca
having demerged from ICI in 1993 - and, on completion of the merger of Astra and Zeneca in April 1999, he became Chief Executive of AstraZeneca PLC, a position he held until retiring on 31 December 2005. He is president of The Science Council in the UK and a non-executive director of Almirall Prodesfarma SA and of UCB Pharmaceuticals. He has previously served as Chairman of the Royal Bank of Scotland, and as a non-executive director of BP plc, Amersham International plc (now GE Healthcare) and Lloyds TSB plc. During his career he has received many scholarly awards and fellowships and was knighted in 2002 for services to the pharmaceutical industry.

Claus Braestrup,
Danish national, born in 1945.

Claus Braestrup holds a Master’s degree in Chemical Engineering and a MSc in Biochemistry. He is Doctor of Medical Science and former Adjunct Professor in Neuroscience at the University of Copenhagen. He started his career in research and consultancy positions. He then moved to Novo Nordisk A/S, where he served as Vice President of Pharmaceutical Research, President of the CNS Division and President of the Diabetes Care Division. He subsequently took the post of Head of Preclinical Drug Research at Schering AG, before joining H. Lundbeck A/S as Executive Vice President, Research and Development. From 2003 – 2008 he was President and CEO of H. Lundbeck A/S. Claus Braestrup is member of the board of the University of Copenhagen, Bavarian Nordic A/S and Santaris A/S.

Nicole Dubois,
US national

Nicole Dubois is a strategy and management consultant to major European and US corporations, in particular in the healthcare sector. She has at different times worked for BCG, in partnership with the Monitor Group, and independently. She has worked with CEOs and executive committees of global Fortune 500 companies, as well as with entrepreneurial entities and non-profit institutions, spanning organisations as diverse as BellSouth, GE, BP, Novartis, Aventis, Save the Children, World Learning etc. For the past 10 years, her main focus has been on the pharmaceutical sector. Her areas
of expertise include strategy implementation, global marketing, executive leadership and post merger integration and transformation. Ms Dubois holds a PhD from the Sorbonne, an MBA from Harvard, and is a graduate of Ecole Normale Supérieure (Ulm). At various times in her career, she has also taught at these institutions or at other universities. She has published a book, Les Multinationales.